Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pentoxifylline

Known as: 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione, 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-, Oxpentifylline 
A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased… Expand
National Institutes of Health

Related topics

Related topics

41 relations

Narrower (8)

8-oxolisofylline8-oxopentoxifyllineAgapurinBL-191
Expand
Brain IschemiaCerebrovascular accidentDiabetic AngiopathiesDiabetic Neuropathies
Expand

Broader (6)

Free Radical ScavengersPharmacologic SubstancePhosphodiesterase InhibitorsPlatelet Aggregation Inhibitors
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The biology and role of CD44 in cancer progression: therapeutic implications
CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2018
Review
2018
Update of pathophysiology and management of diabetic kidney disease.
Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in patients with diabetes mellitus and the leading… Expand
Review
2017
Review
2017
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary
Preamble Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific… Expand
  • table 1
  • table 2
  • table 3
  • table 5
  • table 6
Review
2017
Review
2017
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical…
Jonathan L. Halperin, MD, FACC, FAHA, Chair Glenn N. Levine, MD, FACC, FAHA, Chair-Elect Sana M. Al-Khatib, MD, MHS, FACC… Expand
  • table 1
  • table 2
  • table 3
  • table 3
  • table 5
Highly Cited
2011
Highly Cited
2011
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial
The primary aim of this study was to compare the effects of pentoxifylline (PTX) versus placebo on the histological features of… Expand
Highly Cited
2005
Highly Cited
2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
PURPOSE The primary aim of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 was to determine whether four cycles… Expand
Highly Cited
2003
Highly Cited
2003
Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.
PURPOSE Radiation-induced fibrosis (RIF) is a rare morbid complication of radiotherapy, without an established method of… Expand
Highly Cited
2000
Highly Cited
2000
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.
BACKGROUND & AIMS An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
PURPOSE We performed a randomized, double-blind, placebo-controlled, multicenter trial to evaluate the relative efficacy and… Expand
Highly Cited
1995
Highly Cited
1995
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
The possibility that appropriately designed chemotherapy could act selectively against p53-defective tumor cells was explored in… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE